Chemicon International, Inc. Meets CE Mark Deadline for Its Light Diagnostic Products.

Business Editors/Health/Medical Writers

TEMECULA, Calif.--(BUSINESS WIRE)--Dec. 8, 2003

Chemicon International, Inc., a division of Serologicals Corporation (NASDAQ/NM: SERO), announced today that, as required by IVDD directive of the European Union, all qualifying Chemicon International, Inc. in vitro diagnostic (IVD) products have been CE Marked for sales in Europe prior to the December 7, 2003 deadline. Chemicon International, Inc. obtained accreditation to ISO 13485 in November of 2002 enabling the company to CE Mark IVD products according to IVDD directives. The IVD products manufactured by Chemicon International, Inc. are sold under the trade name of "Light Diagnostics(TM)."

The ISO 13485 accreditation is a key requirement of European and other governmental regulatory authorities and the CE Mark allows Chemicon to market and distribute its IVD products in the European Union. ISO 13485 is the international standard for medical device manufacturers, built upon the conventional ISO 9000 system. The ISO 13485 standard complies with specific industry requirements relative to the United States Food and Drug Administration's current Good Manufacturing Practices and Quality System Regulations. Many countries worldwide rely on this standard as recognition of the highest quality control for regulation of medical devices. The successful completion of the ISO 13485 accreditation will increase the potential market for Chemicon's products worldwide, as it demonstrates the company's directive of providing consistent and reliable products.

Chemicon International, headquartered in Temecula, California, USA, is a life science research and diagnostic products company engaged in developing, manufacturing and marketing products that provide innovative tools to accelerate biomedical research. Chemicon's products and services facilitate advancement in cell signaling, cancer, angiogenesis, apoptosis, developmental biology, cellular physiology, cell adhesion, neurobiology, and infectious disease. The company also has state-of-the art cGMP, TGA and ISO approved manufacturing facilities in the United States, Australia, and the United Kingdom. Chemicon supplies a broad selection of proven, top-quality, and consistent diagnostic test reagents for clinical and health organizations worldwide.

About Serologicals and Chemicon

Serologicals Corporation, headquartered in Atlanta, Georgia, is a global provider of biological products and enabling technologies, which are essential for the research, development and manufacturing of biologically based life science products. Customers include many of the leading research institutions and life science companies throughout the world. The Company's products and technologies are used in a wide variety of innovative applications within the areas of neurobiology, cell signaling, cancer, angiogenesis, apoptosis, developmental biology, cellular physiology, oncology, hematology, immunology, cardiology, infectious diseases, and molecular biology. Through its Chemicon Division, the Company also manufactures diagnostic products at its cGMP, ISO, and TGA approved facilities. Chemicon International, Inc., a wholly owned subsidiary of Serologicals Corporation, is headquartered in Temecula, California. Serologicals has more than 800 employees worldwide, and its shares are traded on the NASDAQ national stock market under the symbol SERO. For more information on Serologicals Corporation and Chemicon International, visit the companies' web sites at www.serologicals.com and www.chemicon.com.

Serologicals is a registered trademark of Serologicals Royalty Company.